Artificial intelligence (AI) software developer Lunit plans to partner with the Japan National Cancer Center Hospital East in Chiba on AI pathology algorithms for oncology tissue analysis.
The partnership will incorporate the use of Lunit's Scope, an AI biomarker platform that helps clinicians analyze immunohistochemistry from clinical trials, including the center's molecular profiling initiatives Scrum-Japan and Monstar-Screen, it said. The objective of the collaboration will be to assess the ability of AI to read biomarkers such as HER2 and PD-L1 and evaluate the performance of new biomarkers such as immune phenotypes, according to Lunit.
